Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
James D. Chalmers, Mark L. Metersky, Joseph Feliciano, Carlos Fernández, Ariel Teper, A. Maes, Mariam Hassan, Anjan Chatterjee
Abstract
Bronchiectasis (also referred to as non-cystic fibrosis bronchiectasis [1]) is an inflammatory disease, characterised by permanently dilated bronchi, with chronic cough, sputum production and frequent exacerbations [2, 3]. Increased airway neutrophil elastase (NE) activity is associated with bronchiectasis disease progression and increased risk of pulmonary exacerbations [4, 5]. Brensocatib is an investigational, small-molecule, orally bioavailable, selective, reversible dipeptidyl peptidase 1 inhibitor that blocks activation of neutrophil serine proteases including NE [1, 6, 7]. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. Conflict of interest: J.D. Chalmers has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Zambon and Insmed Incorporated; a grant from Gilead; and personal fees from Novartis and Chiesi within the past 24 months. Conflict of interest: M.L. Metersky has received consulting fees from Insmed Incorporated, Boehringer Ingelheim, California Institute for Biomedical Research and Zambon; and his institution has received clinical trial support from Insmed Incorporated. Conflict of interest: J. Feliciano, C. Fernandez, A. Teper, A. Maes, M. Hassan and A. Chatterjee are employed by Insmed Incorporated.